You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Dow
AstraZeneca
Colorcon
McKinsey
Express Scripts

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

METADATE CD Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Metadate Cd patents expire, and when can generic versions of Metadate Cd launch?

Metadate Cd is a drug marketed by Lannett Co Inc and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has seventeen patent family members in twelve countries.

The generic ingredient in METADATE CD is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

Drug patent expirations by year for METADATE CD
Drug Prices for METADATE CD

See drug prices for METADATE CD

Drug Sales Revenue Trends for METADATE CD

See drug sales revenues for METADATE CD

Recent Clinical Trials for METADATE CD

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Matthew O'BrienPhase 4
National Institute on Drug Abuse (NIDA)Early Phase 1
Craig RushEarly Phase 1

See all METADATE CD clinical trials

Paragraph IV (Patent) Challenges for METADATE CD
Tradename Dosage Ingredient NDA Submissiondate
METADATE CD CAPSULE, EXTENDED RELEASE;ORAL methylphenidate hydrochloride 021259 2007-03-15
METADATE CD CAPSULE, EXTENDED RELEASE;ORAL methylphenidate hydrochloride 021259 2005-05-13

US Patents and Regulatory Information for METADATE CD

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lannett Co Inc METADATE CD methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021259-003 May 27, 2003 AB2 RX Yes No   Start Trial   Start Trial Y   Start Trial
Lannett Co Inc METADATE CD methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021259-004 Feb 19, 2006 AB2 RX Yes No   Start Trial   Start Trial Y   Start Trial
Lannett Co Inc METADATE CD methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021259-001 Apr 3, 2001 AB2 RX Yes No   Start Trial   Start Trial Y   Start Trial
Lannett Co Inc METADATE CD methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021259-002 Jun 19, 2003 AB2 RX Yes No   Start Trial   Start Trial Y   Start Trial
Lannett Co Inc METADATE CD methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021259-006 Feb 19, 2006 AB2 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Johnson and Johnson
McKinsey
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.